Interleukin-8 as a Surrogate Marker in Risk Stratification of Patients with Acute Myeloid Leukemia

M. Almorish, W. Al-Kahiry, M. Rabie, E. Dammag
{"title":"Interleukin-8 as a Surrogate Marker in Risk Stratification of Patients with Acute Myeloid Leukemia","authors":"M. Almorish, W. Al-Kahiry, M. Rabie, E. Dammag","doi":"10.4172/2165-7831.1000240","DOIUrl":null,"url":null,"abstract":"Introduction: When molecular and cytogenetic studies are not available, the risk stratification of AML patients will be difficult. This study was conducted to evaluate the prognostic value of IL-8 among AML patients with its relation to outcome. Methods: This is a cross sectional study; 42 newly diagnosed AML patients (<65 years) were investigated with determination of serum IL-8 by ELISA and followed up for 36 months. In addition, 20 sex and age matched normal volunteers were included as control. Results: In AML patients, serum IL-8 was ranging from 5 to 200 pg/mL with a mean of 76.5 pg/mL. It was significantly higher among AML patients when compared to the control (76.5 vs 32.3 pg/mL). The mean did not show any significant relationship to patients’ sex or the FAB classification of AML (p>0.05). While significant higher mean was observed among poor cytogenetic risk group (110.4 pg/mL) as well as among died patients (108.8 pg/mL) and refractory patients (84.2 pg/mL). In regard to survival, among those with IL-8>40 pg/mL, the mean survival time was higher in comparison to AML patients with IL-8 ≤ 40 pg/mL (34.6 months vs 26.3 months). Conclusion: This study concluded that serum IL-8 concentration at presentation of AML patients is high and it could be used as a marker for risk stratification for AML patients.","PeriodicalId":90886,"journal":{"name":"Journal of blood & lymph","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of blood & lymph","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2165-7831.1000240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: When molecular and cytogenetic studies are not available, the risk stratification of AML patients will be difficult. This study was conducted to evaluate the prognostic value of IL-8 among AML patients with its relation to outcome. Methods: This is a cross sectional study; 42 newly diagnosed AML patients (<65 years) were investigated with determination of serum IL-8 by ELISA and followed up for 36 months. In addition, 20 sex and age matched normal volunteers were included as control. Results: In AML patients, serum IL-8 was ranging from 5 to 200 pg/mL with a mean of 76.5 pg/mL. It was significantly higher among AML patients when compared to the control (76.5 vs 32.3 pg/mL). The mean did not show any significant relationship to patients’ sex or the FAB classification of AML (p>0.05). While significant higher mean was observed among poor cytogenetic risk group (110.4 pg/mL) as well as among died patients (108.8 pg/mL) and refractory patients (84.2 pg/mL). In regard to survival, among those with IL-8>40 pg/mL, the mean survival time was higher in comparison to AML patients with IL-8 ≤ 40 pg/mL (34.6 months vs 26.3 months). Conclusion: This study concluded that serum IL-8 concentration at presentation of AML patients is high and it could be used as a marker for risk stratification for AML patients.
白细胞介素-8作为急性髓系白血病患者危险分层的替代标志物
在没有分子和细胞遗传学研究的情况下,AML患者的风险分层将是困难的。本研究旨在评估IL-8在AML患者中的预后价值及其与预后的关系。方法:采用横断面研究;新诊断AML患者42例(0.05)。而低细胞遗传风险组(110.4 pg/mL)、死亡患者(108.8 pg/mL)和难治性患者(84.2 pg/mL)的平均值均显著升高。在生存方面,与IL-8≤40 pg/mL的AML患者相比,IL-8≤40 pg/mL的患者平均生存时间更高(34.6个月vs 26.3个月)。结论:本研究提示AML患者发病时血清IL-8浓度较高,可作为AML患者危险分层的标志。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信